Tabitha E. H. Moses, MS joins Ethics Talk to discuss her article, coauthored with Dr Arash Javanbakht: “How Should Clinicians Determine a Traumatized Patient’s Readiness to Return to Work?”
Clinicians with obligations to patients and to organizations often assess patients in law enforcement for both therapeutic and nontherapeutic purposes.
AMA J Ethics. 2022;24(2):E111-119. doi:
10.1001/amajethics.2022.111.
Therapeutic security in inpatient psychiatric settings requires careful planning and implementation if it is to support both patients’ safety and dignity.
AMA J Ethics. 2024;26(3):E205-211. doi:
10.1001/amajethics.2024.205.
Nubia Chong, MD, Maria Mirabela Bodic, MD, Peter Steen, MD, Ludwing Salamanca, MD, PhD, and Stephanie LeMelle, MD, MS
Paternalistic language in patients’ health records is of specific ethical concern because it emphasizes clinicians’ power and patients’ vulnerabilities and can be demeaning and traumatizing.
AMA J Ethics. 2024;26(3):E225-231. doi:
10.1001/amajethics.2024.225
Inpatient psychiatric units are designed around the twin aims of treatment and containment, but emotional norms and tone also contribute to care environments.
AMA J Ethics. 2024;26(3):E232-236. doi:
10.1001/amajethics.2024.232.
Dr Brendan D. Kelly joins Ethics Talk to discuss his article, coauthored with Dr Róisín Plunkett: “Should Dignity Preservation Be a Precondition for Safety and a Design Priority for Healing in Inpatient Psychiatry Spaces?”
Daphne C. Ferrer, MD and Peter M. Yellowlees, MBBS, MD
Telepsychiatry extends access to psychiatric treatment to those who might not otherwise get it, but licensure problems and the risk of boundary violations between patients and physicians need to be worked out.
B. Rashmi Borah, Nicolle K. Strand, JD, MBioethics, and Kata L. Chillag, PhD
The Bioethics Commission’s recommendations to include research participants with impaired consent capacity provide an ethical foundation for neuroscience.
AMA J Ethics. 2016;18(12):1192-1198. doi:
10.1001/journalofethics.2016.18.12.nlit1-1612.
Physicians are obligated to inform patients involved in a clinical trial that there is a chance of receiving a placebo, which can result in a deterioration of a medical condition.